Start here: the honest default
No treatment is approved for long COVID, and this strategy is still being tested. Both its grade and its audit read as pending, and that is not an oversight: the results that would settle it are not in yet.
What makes this approach compelling is that it aims at a root cause rather than a symptom. What makes it uncertain is that the root cause itself, a clearable reservoir, is still a hypothesis.
The idea behind it
If viral persistence keeps the immune system and blood vessels switched on, then removing the reservoir, with longer or stronger antiviral courses, or with monoclonal antibodies that mop up virus, could address the cause instead of managing the consequences.
It is the most biologically ambitious approach in the pipeline, and the rationale is laid out clearly in the literature.1 Ambition and proof are different things.
grade pendingaudit pendingtrials underway
Where the evidence stands
The trials are underway, and as of now there is no positive readout. Promising laboratory logic has not yet become a working treatment, and it may not, because the reservoir could be hard to reach, harmless, or not present in everyone.
This is the honest shape of frontier science: a strong idea being tested in real time, with the answer genuinely unknown rather than quietly settled.
Where a reservoir could hide
Part of what makes this strategy so hard to prove is that the reservoir, if it exists, may sit in places that are difficult to sample. The gut wall, lymphoid tissue, nerve tissue, and other protected niches could each harbor lingering virus or viral proteins, and none of them is fully accessible to an ordinary blood test or even a stool sample.
That hiddenness shapes the entire effort. It is why proving a reservoir is present, measuring whether a treatment actually cleared it, and then linking that clearance to a change in symptoms are all genuinely difficult tasks rather than routine ones. The trials in this space are as much about developing ways to measure persistence as they are about the drugs themselves, which is part of why clean answers have been slow to arrive.
What the trials are testing
The trials broadly fall into two families aimed at the same target from different angles. One uses extended or stronger antiviral courses meant to suppress any ongoing viral replication; the other uses monoclonal antibodies designed to bind and clear lingering virus or its proteins. Both rest on the same premise, that removing a persistent reservoir could treat long COVID at its root rather than chasing its symptoms.
So far none has produced a positive readout, and both the grade and the audit for this approach read as pending. That is not the same as failure, because the trials are ongoing and the underlying idea is among the most biologically serious in the field. But it is a clear reason to hold reservoir-targeting treatment as a hypothesis under active test rather than an available option, and to be wary of pursuing extended antiviral courses outside a study.
Why this belongs in a trial
Because there is no demonstrated benefit yet, the right home for reservoir-targeting antivirals is a clinical trial, where dosing is controlled, effects are measured against a comparison group, and safety is monitored. Pursuing long antiviral courses on your own means taking on real drug risks for a benefit that has not been shown to exist, and without the measurement that would tell you whether it helped.
The most useful thing you can do with this idea is follow the trials closely and, if you are eligible and willing, consider joining one. That gives you access under proper monitoring and helps produce the answer the whole field is waiting for. Framed honestly, this is the most promising unproven approach in long COVID: promising enough to take seriously, unproven enough to keep inside a study rather than a prescription.
What to weigh
Because there is no proven benefit yet, the right place for reservoir-targeting antivirals is a clinical trial, where dosing is controlled and effects are measured. Pursuing extended antiviral courses outside a study means taking on real drug risks for a benefit that has not been demonstrated.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether a clearable viral reservoir exists in most people with long COVID, or only some.
- Which drug, dose, and duration could actually reach and clear it.
- Whether clearing the reservoir reverses symptoms or leaves downstream damage in place.
- How to measure success without an accessible, validated reservoir test.
- Whether antibodies, antivirals, or a combination is the better tool.
- Whether any benefit would be durable or fade once treatment stops.
What this means for you
If you are drawn to reservoir-targeting treatment, the honest status is that it is the field's most promising unproven idea. That phrasing is deliberate: promising enough to take seriously, unproven enough that it belongs in a trial rather than a prescription.
The most useful thing you can do is watch the trials and, if you are eligible and willing, consider joining one. That gives you access under monitoring and helps produce the answer the whole field is waiting for.
References
Each reference links to the source on PubMed, PMC, or the publisher.